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Abstract
Background: Trivalent Influenza Virus Vaccine (FLU3) is a traditional flu vaccine to protect people against three
different flu viruses, including influenza A H1N1 virus, an influenza A H3N2 virus and one B virus.
Methods: We searched Vaccine Adverse Event Reporting System (VAERS) for US reports after FLU3 vaccination in
the year of 2011. We conducted descriptive analyses on symptoms from serious reports (i.e., death, life-threatening
illness, hospitalization, prolonged hospitalization, or permanent disability). We then further grouped these symptoms to
the System Organ Classes (SOC) based on the MedDRA Terminology using NCBO Web Services. We fitted zero-truncated
Poisson regression models to estimate the average number of symptoms per subject and compared it across different
age groups and between genders. In addition, we compared the risk of occurrence for an SOC across different age
groups and between genders by using logistic regression models. Finally, we constructed the pairwise correlation matrix
of the SOCs by calculating Spearman’s rank correlation coefficients.
Results: We identified 638 unique serious FLU3 reports from year 2011. There are 1410 unique symptoms from these
reports. Descriptive statistics shows that the most common symptom and symptom pair are Pyrexia and Guillain-Barre
syndrome – Hypoesthesia respectively. The estimated average number of symptoms per subject in the study cohort is
8.74 (95 % CI 6.76, 10.73). There are statistically significant differences in number of symptoms among four age groups
and between genders. Age category and gender are significantly associated with several individual SOCs. Pairwise
correlation matrix shows that “Endocrine disorders” and “Neoplasms benign, malignant and unspecified (incl cysts
and polyps)” are strongly correlated.
Conclusions: This paper reports a novel method that combining statistical analyses with terminology grouping
using VAERS data. The analyses revealed differences of reactions among different age groups and between genders
and correlation on both symptoms and System Organ Class level independently. The results may lead to additional
studies to uncover factors contributing to the individual differences in susceptibility to influenza infection. This method
can also be applied to other vaccine types and conduct similar analysis.
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Background
Influenza (flu) is a contagious respiratory illness caused
by influenza viruses, which may cause mild to severe ill-
ness including hospitalization or even death. Certain
groups of people, such as the elders, young children, and
those with certain health conditions, are at high risk for
serious flu complications [1]. The primary and most
used method for the control of influenza and its compli-
cations are influenza vaccines. Over the years, hundreds
of millions of Americans have received seasonal influenza
vaccines to protect themselves against the flu viruses.
Commonly, the side effects following flu vaccinations are
mild, including symptoms such as soreness, redness or
swelling at the injection sites, headache, muscle aches and
nausea after the shot. Serious adverse reactions, however,
could happen, which may cause some life-threating illness
even death.
Clinical trials are generally not large enough to detect
rare influenza vaccine adverse events. In 1990, Vaccine
Adverse Event Reporting System (VAERS) was created
as a passive surveillance system to accept reports of
adverse events following any US licensed vaccines form
providers, health care workers, and the public [2]. VAERS
is co-administered by Center for Disease Control and
Prevention (CDC) and the Food and Drug Administration
(FDA). It is one of the largest databases containing adverse
events reported in temporal association with vaccination.
Since 1990, VAERS has received more than 400,000 vac-
cine adverse event reports, which makes it one of the most
important sources to detect rare vaccine adverse events.
Although VAERS cannot usually prove the causal relation-
ships between vaccines and adverse events, it could be
used to detect signals to be tested with more rigorous
methods [3].
For years, trivalent Influenza Virus Vaccine (FLU3) is
the traditional flu vaccine to protect people against three
different flu viruses, including an influenza A H1N1
virus, an influenza A H3N2 virus and one B virus [4].
Among all the VAERS reports, FLU3 is the most com-
mon vaccine type reported. Thus VAERS is a very im-
portant data source for studying FLU3 adverse events.
Much work has been done on the study of influenza
adverse events using VAERS data [5–7]. Most of them
only deal with some specific symptoms on the FLU3
vaccine adverse reports. A single vaccine and AE associ-
ation, however, should not be considered as an isolated
event. The associations of other vaccines with the same
AE and other AEs with the same vaccine should also be
taken into consideration [8].
Our research takes advantage of the Medical Dictionary
for Regulatory Activities (MedDRA) terminology system
for semantically grouping the VAERS adverse symp-
toms, which are already coded using MedDRA terms
[2]. The MedDRA Terminology is the international
medical terminology developed under the auspices of
the International Conference on Harmonization (ICH)
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use. MedDRA Terminology has a
five-level structural hierarchy. They are lowest Level
Term (LLT), Preferred Term (PT), High Level Term
(HLT), High Level Group Term (HLGT), and System
Organ Class (SOC). VAERSSYMPTOMS contains symp-
toms terms that are in the level of LLT [9]. VAERS used
symptom terms from PT, which always have its own iden-
tical term as LLT. The full MedDRA has 72,637 LLT
symptoms and VAERS uses 9593 of them (13 %) [10].
System organ class (SOC) is the highest level of the hier-
archy that provides the broadest concept for data retrieval,
which comprises grouping by etiology, manifestation site
and purpose. MedDRA has 26 different types of SOCs and
each LLT is at least linked to one SOC [9].
As the number of unique symptoms is relatively large
in VAERS, we consider them in the SOCs to facilitate
further statistical analyses. We leveraged The National
Center for Biomedical Ontology (NCBO) web service to
automatically map LLTs to their corresponding SOCs.
The NCBO offers a range of Web services that would
allow users to access various biomedical terminologies
and ontologies and to identify terms from controlled ter-
minologies and ontologies that can describe and index
the contents of online data sets (data annotation) [11].
All the MedDRA terminology system is stored in JSON
format on the NCBO web services and each term is a
JSON node. We used NCBO web services to search the
hierarchical information of the symptom terms in the
VAERS reports and assigned each symptom term one pri-
mary SOC. After grouping the symptoms to SOCs, we
conducted multiple statistical analyses on the SOC level.
Materials and methods
Data source
We searched the VAERS for US reports after FLU3
vaccination in year 2011 and extracted serious reports
(i.e., death, life-threatening illness, hospitalization, pro-
longed hospitalization, or permanent disability). VAERS
raw data of each year contains three Comma-separated-
value (CSV) files: VAERSDATA.CSV, VAERSVAX.CSV
and VAERSSYMPTOMS.CSV. VAERSDATA is about the
patients’ demographic information, lab test, symptom
text and outcomes. VAERSVAX is about vaccine types.
VAERSSYMPTOMS is about symptoms that are equi-
valent to the PT TERM from the MedDRA codebook.
These three tables are linked by using VAERS_ID. For
each report, the VAERS also provides annotations for
post-vaccination symptoms in MedDRA terms. To fa-
cilitate further statistical analyses, we further grouped
these symptoms based on the MedDRA SOC using the
NCBO Web Services [11].
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Descriptive analysis
We calculated descriptive statistics including the num-
ber of reports, symptoms, and unique symptoms in the
selected reports. We also calculated the frequency of
each symptom and co-occurrence of symptom pairs.
We grouped the reports in five age groups based on
cut points (0.5, 17, 49, 64) suggested by CDC [12]. The
frequency of observations in age category (0 to 0.5) is
relatively small (n = 14) compared to other age categories.
In order to be consistent with our previous analysis, we
excluded those subjects in our data analysis, which lead to
1663 subjects [13].
Grouping symptoms using MedDRA terminology
SOC is the highest level of the MedDRA terms, which
comprises grouping by etiology, manifestation site or
purpose. Each LLT is linked to only one PT and each PT
is linked to at least one SOC. This indicates that each
LLT could be grouped to more than one SOC. To avoid
double counting, we will need to identify the primary
SOC for each term [9]. The rules to assign SOC to the
symptoms, however, are complicated, which needs expert
reviews that could be time consuming and expensive.
Our study proposed a simple way to group them into
SOCs by using the international agreed order of the
SOC list (see Table 1). The order of the SOCs was based
upon the relative importance of each SOC, which is
determined by the Expert Working Group [9]. First, we
retrieved all possible SOCs a VAERS symptom term be-
longs to. We applied Depth-first Search (DFS) algorithm
by using recursive tree-traversing method to find all
the SOCs that is linked by a symptom term. If one
symptom term belongs to several SOCs, we choose the
SOC that ranked highest as its primary SOC. If a re-
port has N symptoms that belong to the same specific
SOC, we count N times of that specific SOC. Table 2
shows the sample data set (partial) we prepared for
further analysis.
Statistical methods
After grouping the symptoms into 26 SOCs, we explored
the grouped data with regression models and correlation
analysis. Specifically, we estimated the average number
of symptoms per subject given stratified age groups and
gender. For individual SOC, we fitted logistic regression
to evaluate the association of occurrence of an SOC with
age and gender. A rank-based correlation matrix is also
estimated to investigate the correlation among SOCs.
Zero-truncated Poisson regression
As each subject has at least one SOC to be reported
(i.e. the number of SOCs > 0), we fitted a zero-truncated
Poisson regression model (a modified model of Poisson re-
gression by excluding the probability mass at 0) to conduct
Table 1 International Agreed Orders of SOCs
SOC Order
Infections and infestations 1
Neoplasms benign, malignant and unspecified
(incl cysts and polyps)
2
Blood and lymphatic system disorders 3
Immune system disorders 4
Endocrine disorders 5
Metabolism and nutrition disorders 6
Psychiatric disorders 7
Nervous system disorders 8
Eye disorders 9
Ear and labyrinth disorders 10
Cardiac disorders 11
Vascular disorders 12
Respiratory, thoracic and mediastinal disorders 13
Gastrointestinal disorders 14
Hepatobiliary disorders 15
Skin and subcutaneous tissue disorders 16
Musculoskeletal and connective tissue disorders 17
Renal and urinary disorders 18
Pregnancy, puerperium and perinatal conditions 19
Reproductive system and breast disorders 20
Congenital, familial and genetic disorders 21
General disorders and administration site conditions 22
Investigations 23
Injury, poisoning and procedural complications 24
Surgical and medical procedures 25
Social circumstances 26
Table 2 Sample data set we prepared for further analysis
(partial, data of year 2011)
ID …… SOC7 SOC8 SOC9 SOC10 ……
413830 0 1 0 0
413836 0 0 0 0
413913 0 3 0 0
413937 0 11 0 2
413946 0 5 1 0
413959 0 5 0 0
413966 3 15 3 0
413993 1 5 0 0
413994 1 3 0 0
…… ……
ID refers to the report ID number. The number in a cell refers to the number
of appearance in the corresponding SOC in that report
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data analysis [14]. Firstly, we fitted a model with intercept
only to estimate the average number of symptoms for all
subjects. After that, we included covariates of age category
and gender in the model to estimate and compare the
number of symptoms in different age and gender strata.
Logistic regression
To explore the association of the occurrence of individual
SOC with age and gender, we conducted a logistic regres-
sion with covariates of age group and gender [15]. The
original count number of SOC is dichotomized into binary
outcomes (1: SOC ≥ 1, 0: SOC = 0).
Spearman rank correlation coefficient
As the number of SOCs is highly right skewed and non-
normally distributed, we use a nonparametric correlation
coefficient to measure the correlation structure among
SOCs. This rank based correlation coefficient is known as
Spearman’s ρ [16]. We constructed a correlation matrix
of SOCs to present the pairwise correlation coefficients
between SOCs.
Results
During the study period (year 2011), VAERS received
7986 FLU3 reports; 638 were serious. Out of the 638 re-
ports, 324 were for female patients, 295 were for male
patients, and 19 were for unknown sex, see Fig. 1. Out
of these reports, there were 5447 symptom terms (not
unique) appeared in total, which were grouped into 26
SOCs. The most frequent SOCs in the 638 reports are
nervous system disorders, general disorders, and admin-
istration site condition and investigations. Please note
that some symptom terms cannot be grouped to any
MedDRA SOCs. There were 48 symptom terms (21 of
them are unique) can’t be mapped into MedDRA SOCs,
including “Drug exposure during pregnancy”, “Herpes
zoster multi-dermatomal” and etc. (The complete list
can be seen in Additional file 1: Table S1A). This may
due to the MedDRA version differences between the
NCBO Web Services and VAERS. As the number of
these symptoms is relatively small (0.9 %), we did not
take these symptoms into consideration.
We then calculated the frequency of each symptoms
and symptom concurrences. The most frequent symp-
toms happened after FLU3 vaccination in year 2011
were Pyrexia (131 times), Hypoaesthesia (95 times), and
Guillain-Barre syndrome (90 times), the visualization
result can be seen in Fig. 2. (The complete results can
be seen in Additional file 1: Table S1B). The most fre-
quent symptom co-concurrences were Guillain-Barre
syndrome + Hypoaesthesia (24 times).
Analysis using zero-truncated Poisson model with
intercept only indicated that the estimated average num-
ber of symptoms per subject in the study cohort is 8.74
(95 % CI: 6.76, 10.73). The results from fitting zero-
truncated Poisson regression with covariates age groups
and gender suggest that there are statistically significant
differences in the numbers of symptoms among four age
Fig. 1 Descriptive results of 2011 VAERS FLU3 data. a the proportion of serious reports of the total FLU3 reports. b the gender distribution of
these serious reports. c the age distribution of these serious reports
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groups and between different genders. The average num-
ber of symptoms per year for a female patient with age
between 0.5 years and 17 years is estimated as 7.76
(95 % CI: 5.76–9.76). We use this group as the reference
age group. The youngest age group (0.5–17 years) has
the smallest number of symptoms per year, followed by
age group 4 (>64 years), age group 2 (17–49) and finally
age group 3 (49–64 years). The average number of
symptoms for subjects of 17–49 years old is 1.13 times
of the average number of symptoms for subjects of 0.5–
17 years old with the same gender. This is consistent
with previous reports about different immune responses
after vaccination for different age groups. For example,
there is high-dose influenza vaccine available for elders
(>65) because ageing decreases the body's ability of im-
mune response after vaccination [17]. In addition, the
males have 3.2 % lower number of symptoms. This is
also consistent with previous studies that female experi-
ence more adverse reactions to influenza vaccine [18].
We plotted the estimated residuals versus fitted values
of zero-truncated Poisson regression mode. We found
that the residuals are generally small and scattered
around zero for most of the data points with only a few
extreme values. This suggests that the zero-truncated
Poisson regression model may fit the data well.
Analysis on individual SOCs also revealed some in-
teresting results. Overall, there are 15 SOCs that show
significant association with the age groups or between
genders. The males have fewer responses for most SOCs
except SOC1 (infections and infestations, 48.1 % more).
Males are 0.369, 0.552 and 0.535 times less likely to have
SOC 9 (Eye disorders), SOC 11 (Cardiac disorders) and
SOC 12 (Vascular disorders) than females respectively.
For SOC 14 (Gastroin-testinal disorders) and SOC 1
(Infections and infestations), female has significant
higher possibilities than male. For SOC 1 (Infections
and infestations), SOC 9 (Eye disorders), SOC 12 (Vascular
disorders), and SOC 17 (Musculoskeletal and connective
tissue disorders), people who are older than 17 show sig-
nificant higher possibilities to get those adverse symptoms.
Age group 3 (49–64) shows significant higher chance of
experiencing symptoms relevant to infections and infesta-
tions, immune system disorders, eye disorders, vascular
disorders, musculoskeletal and connective tissue disorders,
surgical and medical procedures, and social circumstances
compared to age group 1 (0.5–17) with the same gender.
To evaluate the overall goodness of fit of the logistic
regression model for each SOC, we conducted Hosmer-
Lemeshow test [15] and calculated the corresponding p-
values. Most of the p-values for all 26 tests are much
smaller than 0.05, which suggests that the logistic regres-
sion model fits the data well.
We also calculated the pairwise correlation matrix of
SOCs determined by Spearman’s method [16]. Fig. 3
shows the correlation plot. The color and area of spot
represents the strength of correlation between SOCs.
The threshold to assert a correlation used by us is
whether the correlation coefficient is larger or equal
than 0.2 as suggested by Evans [19]. As illustrated in
Fig. 3, SOC 5 (Endocrine disorders) has the strongest
correlation with SOC 2 (Neoplasms benign, malignant
and unspecified (incl cysts and polyps)). Besides, we
find that SOC 23 (Investigations) has a correlation with
SOC 8 (Nervous system disorders). We can also find
that SOC 22 (General disorders and administration site
conditions) has correlations with SOC6 (Metabolism
and nutrition disorders), and SOC 17 (Musculoskeletal
and connective tissue disorders). In addition, SOC 12
Fig. 2 Symptoms frequency visualization for year 2011, the bigger the frequency the larger the font size of that symptom
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(Vascular disorders) shows correlations with SOC 3
(Blood and lymphatic system disorders), and SOC 6
(Metabolism and nutrition disorders). In addition, SOC
18 (Renal and urinary disorders) has correlations with
SOC 3 (Blood and lymphatic system disorders), SOC 6
(Metabolism and nutrition disorders) and SOC 12
(Vascular disorders).
Conclusions and future work
This paper reports a novel method that combining stat-
istical analyses with terminology grouping using VAERS
data to study Trivalent Influenza Vaccine. Our prelimin-
ary statistical analyses reveal differences of reactions
among different age groups and between genders. To
our best knowledge, there are very few studies about the
adverse events analysis on MedDRA SOC level. Most of
our findings on the relationship between adverse events
with individual difference have not been reported by
other studies. The results may lead to additional studies to
uncover factors contributing to the individual differences
in adverse reactions to influenza vaccination.
For the limitations of this paper, due to the multiple
inheritance nature of MedDRA, many symptom terms
can be mapped to more than one SOCs. The order list
we used to assign the primary SOC may be subjective.
Ontology of Adverse Events (OAE) could provide a better
hierarchy than MedDRA. The current version of OAE,
however, does not include all the symptoms in the VAERS
(coded in MedDRA) yet. We will consider using OAE to
map the symptom terms as the OAE grows.
There are a few future directions we would like to
pursue: (1) we will extend and apply the methodology
to more VAERS reports over different years; and (2)
this method can also be applied to other vaccine types
and conduct similar analysis.
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